miR-133b targets MET in CRC cells [70]; PKM2 in tongue SCC [68]; FSCN1 in ESCC [69] and myeloid cell leukemia sequence 1 (MCL1); and BCL2-like 2 (BCL2L2) in lung cancer [79]. Here, BCL2L2 is linked to tongue squamous cell carcinoma.